Synapse

← Cancer Drug Resistance

Papers in Cancer Drug Resistance

Page 6 · newest first

  1. Auranofin and its analogs as prospective agents for the treatment of colorectal cancerCancer Drug Resistance · 2022
  2. Role of prostate cancer stem-like cells in the development of antiandrogen resistanceCancer Drug Resistance · 2022
  3. Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approachCancer Drug Resistance · 2022
  4. AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance?Cancer Drug Resistance · 2022
  5. Role of extracellular vesicles secretion in paclitaxel resistance of prostate cancer cellsCancer Drug Resistance · 2022
  6. Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancerCancer Drug Resistance · 2022
  7. Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistanceCancer Drug Resistance · 2022
  8. Understanding sarcoma drug resistance one cell at a timeCancer Drug Resistance · 2022
  9. Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancerCancer Drug Resistance · 2022
  10. Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapyCancer Drug Resistance · 2022
  11. New insights for drug resistance in metastatic castration-resistant prostate cancerCancer Drug Resistance · 2022
  12. Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”Cancer Drug Resistance · 2022
  13. ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo modelCancer Drug Resistance · 2021
  14. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancerCancer Drug Resistance · 2021
  15. How to win the ovarian cancer stem cell battle: destroying the rootsCancer Drug Resistance · 2021
  16. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapyCancer Drug Resistance · 2021
  17. Drug resistance in targeted cancer therapies with RAF inhibitorsCancer Drug Resistance · 2021
  18. Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphomaCancer Drug Resistance · 2021
  19. Curcumin: reclaiming the lost ground against cancer resistanceCancer Drug Resistance · 2021
  20. Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancerCancer Drug Resistance · 2021
  21. EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancerCancer Drug Resistance · 2021
  22. Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor responseCancer Drug Resistance · 2021
  23. Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatmentCancer Drug Resistance · 2021
  24. Barriers to achieving a cure in lymphomaCancer Drug Resistance · 2021
  25. Overcoming drug resistance by targeting protein homeostasis in multiple myelomaCancer Drug Resistance · 2021
  26. Gene expression profiling as a prognostic tool in multiple myelomaCancer Drug Resistance · 2021
  27. ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcomeCancer Drug Resistance · 2021
  28. Experimental models of endocrine responsive breast cancer: strengths, limitations, and useCancer Drug Resistance · 2021
  29. History of intraperitoneal platinum drug delivery for ovarian cancer and its future applicationsCancer Drug Resistance · 2021
  30. Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapyCancer Drug Resistance · 2021
  31. Notch signaling in female cancers: a multifaceted node to overcome drug resistanceCancer Drug Resistance · 2021
  32. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatmentCancer Drug Resistance · 2021
  33. The implication of liquid biopsies to predict chemoresistance in pancreatic cancerCancer Drug Resistance · 2021
  34. Adjuvant role of a T-type calcium channel blocker, TTA-A2, in lung cancer treatment with paclitaxelCancer Drug Resistance · 2021
  35. Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostatCancer Drug Resistance · 2021
  36. Carbonic anhydrase XII inhibition overcomes P-glycoprotein-mediated drug resistance: a potential new combination therapy in cancerCancer Drug Resistance · 2021
  37. Regulation of cancer stem cells in triple negative breast cancerCancer Drug Resistance · 2021
  38. Natural products as a means of overcoming cisplatin chemoresistance in bladder cancerCancer Drug Resistance · 2021
  39. Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancerCancer Drug Resistance · 2021
  40. Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?Cancer Drug Resistance · 2021
  41. The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitorsCancer Drug Resistance · 2021
  42. Shenmai injection enhances cisplatin-induced apoptosis through regulation of Mfn2-dependent mitochondrial dynamics in lung adenocarcinoma A549/DDP cellsCancer Drug Resistance · 2021
  43. Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapyCancer Drug Resistance · 2021
  44. Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistanceCancer Drug Resistance · 2021
  45. Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistanceCancer Drug Resistance · 2021
  46. Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancerCancer Drug Resistance · 2021
  47. The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myelomaCancer Drug Resistance · 2021
  48. Research advances and new challenges in overcoming triple-negative breast cancerCancer Drug Resistance · 2021
  49. Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitroCancer Drug Resistance · 2021
  50. DNA direct reversal repair and alkylating agent drug resistanceCancer Drug Resistance · 2021